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ABSTRACT
Objective: The incidence of esophageal adenocarcinoma (EAC) is increasing, 
but factors contributing to malignant progression of its precursor lesion, Barrett’s 
esophagus (BE), have not been defined. Hypergastrinemia caused by long-term use 
of proton pump inhibitors (PPIs), has been suggested as one possible risk factor. The 
gastrin receptor, CCK2R, is expressed in the cardia and upregulated in BE, suggesting 
the involvement of the gastrin-CCK2R pathway in progression. In the L2-IL-1β mouse 
model, Barrett’s-like esophagus arises from the gastric cardia. Therefore, we aimed to 
analyze the effect of hypergastrinemia on CCK2R+ progenitor cells in L2-IL-1β mice.
Design: L2-IL-1β mice were mated with hypergastrinemic (INS-GAS) mice or 
treated with PPIs to examine the effect of hypergastrinemia in BE progression. CCK2R-
CreERT crossed with L2-IL-1β mice were used to analyze the lineage progenitor 
potential of CCK2R+ cells. Cardia glands were cultured in vitro, and the effect of 
gastrin treatment analyzed. L2-IL-1β mice were treated with a CCK2R antagonist 
YF476 as a potential chemopreventive drug.
Results: Hypergastrinemia resulted in increased proliferation and expansion of 
Barrett’s-like esophagus. Lineage tracing experiments revealed that CCK2R+ cells are 
long-lived progenitors that can give rise to such lesions under chronic inflammation. 
Gastrin stimulated organoid growth in cardia culture, while CCK2R inhibition prevented 
Barrett’s-like esophagus and dysplasia. 
Conclusions: Our data suggest a progression model for BE to EAC in which 
CCK2R+ progenitor cells, stimulated by hypergastrinemia, proliferate to give rise to 
metaplasia and dysplasia. Hypergastrinemia can result from PPI use, and the effects 
of hypergastrinemia in human BE should be studied further.
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INTRODUCTION
The incidence of esophageal adenocarcinoma (EAC) 
has risen 6-fold in the U.S. since the 1970s [1, 2]. Major 
risk factors for EAC include male gender, obesity, and a 
history of gastroesophageal reflux disease (GERD), but 
Barrett’s esophagus (BE) increases the risk of EAC by 
11-fold [3–5]. In BE, present in up to 1.6% of unselected 
populations, the normal squamous epithelium of the lower 
esophagus is replaced by columnar epithelium. However, 
the risk of EAC in patients with nondysplastic BE is quite 
low (0.12% annually) [6]. Screening for dysplasia in BE 
patients has not been shown to decrease mortality [7, 8]. 
Thus, a better understanding is needed of the factors 
involved in neoplastic progression of BE. 
Proton pump inhibitors (PPIs) have been used 
routinely over the last several decades to treat BE patients, 
but their impact on progression of BE remains unresolved. 
PPIs ameliorate reflux symptoms and promote healing of 
esophagitis in most patients over the short term [9], and 
most studies suggest they reduce BE progression. However, 
PPIs cause both acid suppression and a physiologic 
secondary hypergastrinemia, which can lead to extremely 
high plasma gastrin levels in some patients [10, 11]. In 
one study that stratified PPI-treated BE patients by gastrin 
levels, the highest quartile of gastrin levels was associated 
with an increased risk of high-grade dysplasia or EAC on 
biopsy [12]. However, the effect of hypergastrinemia and 
overactive downstream signaling in BE and EAC has not 
yet been demonstrated in experimental models.
The effects of gastrin are mediated by the CCK2R 
(also known as CCKBR), a G-protein coupled receptor 
expressed in the central nervous system and throughout 
the gastrointestinal tract [13]. In the gastric corpus of the 
proximal stomach, the receptor mediates acid secretion 
as well as growth and differentiation of the epithelium. 
[13–15] CCK2R is upregulated in the mucosa during ulcer 
healing, and inhibition impairs mucosal regeneration. 
[16, 17] While CCK2R might in theory mark a short-
lived progenitor cell that expands during healing, we have 
recently shown that CCK2R marks a +4 gastric antrum 
progenitor, which is Lgr5neg or low and lineage traces entire 
antral glands [18]. These CCK2R+ progenitors in the 
gastric antrum can undergo interconversion to Lgr5+ cells 
and contribute to gastric cancer development. However, 
the role of CCK2R in the gastric cardia and BE has not 
been clarified.
CCK2R is upregulated 2-fold in human BE tissues, 
and mediates gastrin-induced proliferation and anti-
apoptotic effects in primary cultures of BE biopsies [19]. 
In addition, CCK2R is upregulated in the gastric cardia of 
mice with Barrett’s metaplasia, and this effect is enhanced 
with administration of bile acids [20]. Studies in animal 
models of gastrointestinal cancer have demonstrated that 
CCK2R signaling can accelerate tumorigenesis in vivo, such 
as in gastrin-overexpressing INS-GAS mice that develop 
proximal gastric cancers [21]. 
The L2-IL-1β transgenic mouse model develops 
Barrett’s-like metaplasia in response to constitutive 
expression of the pro-inflammatory cytokine IL-1β in 
the squamous mucosa of the esophagus and forestomach 
[20]. Mouse and human anatomy differ in that squamous 
mucosa in mouse stomach extends partway into the 
anatomical stomach; however metaplasia and dysplasia 
develop at the gastroesophageal junction in humans and 
the L2-IL-1β mice develop a similar phenotype at the 
squamocolumnar junction, with changes throughout the 
junction between the forestomach/esophagus and the 
columnar stomach. In this model, gastric progenitors 
migrate from below the squamocolumnar junction (SCJ) 
proximally into the esophagus, giving rise to columnar and 
mucus (similar to intestinal) metaplasia. Inducible lineage 
tracing has demonstrated that Barrett’s-like lesions in 
L2-IL-1β mice can arise from Lgr5+ cells in the cardia, 
although other progenitor markers including CCK2R, 
were also upregulated in the cardia [20]. Thus, while 
cardia glands may be structurally similar to antral glands 
and express CCK2R, the precise role or expression pattern 
of CCK2R in the cardia and Barrett’s esophagus has not 
been defined.
RESULTS
Hypergastrinemia accelerates the development 
of Barrett’s-like metaplasia in mice
In order to test the effect of PPI treatment and 
subsequent hypergastrinemia on development and 
progression of Barrett’s-like esophagus, bile acid-treated 
WT and L2-IL-1β mice were given omeprazole for three 
months (Figure 1A). Omeprazole treatment increased 
plasma gastrin levels compared to untreated controls, 
as seen in human patients (Figure 1B). As reported 
previously, bile acid treatment induced hyperplastic 
mucosa extending proximal to the SCJ. Omeprazole 
treatment accelerated metaplastic and dysplastic changes, 
leading to increased mitotic figures, loss of cell polarity, 
and hyperchromatic nuclei (Figure 1C). Omeprazole-
treated mice had higher dysplasia scores and a reduced 
percentage of mucus producing cells compared to 
untreated mice (Figure 1C–1E). Barrett’s-like esophagus 
with increased dysplasia has lower levels of mucus cell 
differentiation, with fewer cells resembling the goblet 
cells in human BE, and thus the G/C ratio (goblet-like 
cell/columnar cell) quantifies this lesser degree of cellular 
differentiation.
While PPIs strongly suppress acid secretion, 
leading to numerous changes in gastric physiology, 
we hypothesized that PPI-related hypergastrinemia 
was primarily responsible for the acceleration of BE 
in mice. To address the role of genetically-induced 
hypergastrinemia on the progression of BE, we crossed 
INS-GAS mice, overexpressing amidated gastrin under 
Oncotarget205www.impactjournals.com/oncotarget
the transcriptional control of the rat insulin promoter 
[22], with L2-IL-1β mice. Plasma gastrin levels were 
significantly higher in L2-IL-1β/INS-GAS mice compared 
to L2-IL-1β mice (Figure 1F). Hypergastrinemia alone 
was not sufficient to induce metaplastic or dysplastic 
cells at the SCJ of INS-GAS mice, whereas the addition 
of hypergastrinemia to the chronic inflammation/BE 
phenotype led to a marked expansion of Barrett’s-like 
esophagus in L2-IL-1β/INS-GAS mice compared to 
L2-IL-1β mice (Figure 1G). This expanded BE occurred in 
a region where we previously did not observe metaplasia or 
dysplasia in INS-GAS mice [22]. Mucus cell differentiation 
was reduced in L2-IL-1β/INS-GAS mice compared to 
L2-IL-1β mice, suggesting that hypergastrinemia inhibits 
the intestinal differentiation typically seen in BE patients. 
We have previously shown that inhibition of Notch 
signaling through a gamma-secretase inhibitor (GSI) can 
inhibit proliferation and induce more classical intestinal 
differentiation in the L2-IL-1β mouse model [20]; this was 
also true for IL-1β/INS-GAS mice, where GSI-treatment 
led to a marked increase in Muc-2 and Alcian blue-
positive metaplastic cells in the mouse cardia (Figure S2), 
consistent with an intestinally differentiated Barrett’s-like 
phenotype. CD44, a potential progenitor cell marker, is 
normally expressed in undifferentiated cells near the base 
of cardia glands, and is also found in gastric dysplasia 
and cancer. In our model, CD44+ cells were expanded in 
L2-IL-1β mice, with a further increase in CD44+ cells 
in L2-IL-1β/INS-GAS mice (Figure 1H), supporting the 
notion that hypergastrinemia promotes the development of 
a less differentiated, hyperproliferative type of Barrett’s-
like esophagus, with a low G/C ratio.
Gastrin-dependent expansion of CCK2R+ cells 
in Barrett’s-like metaplasia
Since Barrett’s-like esophagus appeared to be 
accelerated by hypergastrinemia, we examined the 
expression of the gastrin receptor (CCK2R) in epithelial 
cells in the mouse cardia and in human BE. First we 
examined CCK2R expression in wild type mouse gastric 
cardia by immunohistochemistry, which showed rare 
cells in the cardia glands (Figure 2A). Examination of the 
L2-IL-1β mouse cardia showed some expansion of 
CCK2R+ cells in the inflamed cardia (Figure 2A, 2B). 
To further test the effect of gastrin in these CCK2R+ 
cells, WT and L2-IL-1β mice were infused with gastrin 
(5 ug/kg/h/day) and/or a CCK2R antagonist YF476 for 
7 days. While gastrin treatment had a minimal effect on 
the number of CCK2R+ cells in WT mice, the number of 
CCK2R+ cells in L2-IL-1β mice was increased by gastrin 
infusion (Figure 2A, 2B). Epithelial proliferation in the 
gastric cardia as measured by Ki67 immunostaining was 
increased by gastrin infusion, and blocked by simultaneous 
YF476 administration (Figure 2C, 2D). Interestingly, the 
expression of cardia stem cell marker Lgr5 was markedly 
upregulated in hypergastrinemic mouse cardia, along with 
CCK2R (Figure 2E).
We next stained various human biopsy samples for 
CCK2R by in situ hybridization. Similar to the mouse 
stomach, the normal human cardia contains CCK2R+ 
cells near the base of the glands (Figure 2F). The numbers 
of CCK2R+ cells in human BE, relative to the gastric 
cardia, are increased with either incomplete and complete 
intestinal metaplasia, and further evident in esophageal 
adenocarcinoma arising from BE (Figure 2G–2H). 
These results suggest that CCK2R+ cells can expand 
in cardia glands during BE progression in response to 
hypergastrinemia.
CCK2R marks long-lived progenitors in cardia 
and gives rise to Barrett’s-like metaplasia
We then sought to understand the role of CCK2R+ 
cells in the cardia of wild type mice and in Barrett-s 
like esophagus in L2-IL-1β mice. We hypothesized that 
CCK2R+ cells might act as progenitors in the cardia 
(as previously demonstrated in the gastric antrum [23]) 
and analyzed the cell fate of CCK2R+ cells in mice. 
We utilized CCK2R-CreERT; R26-TdTomato mice 
[23] and examined lineage tracing of CCK2R+ cells by 
administering tamoxifen at 6 weeks of age. Similar to 
CCK2R staining, rare recombined cells were visible 
near the base of the cardia 24 hours after induction 
(Figure 3A). By days 7 and 30, these Tomato-red cells 
expanded and moved upward in the cardia gland until 
almost all the cells in the gland were labeled. Tomato-
red cells persisted for up to one year, showing that 
CCK2R+ cells are long-lived gastric progenitors in 
cardia (Figure 3A). Similar tracing events were observed 
when another Rosa26 reporter line CCK2R-CreERT; 
Rosa26rmTmG mice were used (Figure S3). Another 
mouse line expressing constitutive Cre-recombinase 
under the CCK2R promoter also confirmed the expression 
in cardia progenitors (Figure 3B). We isolated and 
cultured cardia glands from CCK2R-CreERT/R26-mTmG 
mice after tamoxifen induction and observed that CCK2R+ 
cells rapidly expanded and lineage traced cultured cardia 
organoids (Figure 3C), indicating that these cells represent 
progenitor cells with lineage tracing capability. 
To determine whether Barrett’s-like esophagus 
arises from CCK2R+cells in the cardia, we crossed 
L2-IL-1β to CCK2R-CreERT/R26-TdTomato mice. In these 
mice, TdTomato expression was present in cardia 24 hours 
after tamoxifen induction, and within a few weeks 
expanded to entire BE glands. In bile-acid treated L2-IL-
1β/CCK2R-CreERT/R26-TdTomato mice, CCK2R+ cells 
expanded towards the squamocolumnar junction within 
90 days (Figure 3D). At one year, the lineage-traced 
lesions in the cardia of L2-IL-1β mice were CK20-positive 
and p63-negative metaplasia (Figure 3E). These results 
suggest that CCK2R+ progenitors from the cardia can 
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give rise to Barrett-s like esophagus in response to chronic 
inflammation. 
In previous studies we showed that LGR5 is 
upregulated in biopsies of human BE, and Lgr5+ stem 
cells can lineage trace the cardia and BE lesions in 
L2-IL-1β mice. Since both Lgr5 and CCK2R mark cardia 
progenitor cells, we tested whether there is any overlap 
between Lgr5+ and CCK2R+ cells in the cardia gland. We 
stained Lgr5-DTR-GFP mouse stomach for CCK2R, and 
confirmed that the majority of CCK2R+ cells in the cardia 
(approximately 85%) are Lgr5-negative (Figure 3F). 
Thus, these represent two distinct stem cell pools that 
can lineage trace the cardia gland. We next generated 
CCK2R-CreERT/Lgr5-DTR-GFP/R26-TdTomato mice, 
and administered tamoxifen. At early time points, 
there were no recombined red cells in the Lgr5+ green 
population; however, CCK2R+ stem cells gave rise to 
Lgr5+ cells at the base after 30 days (Figure 3G). A similar 
expression pattern for Lgr5 and CCK2R lineages was 
demonstrated by in situ hybridization in CCK2R-CreERT/
R26-TdTomato mice (Figure S4), suggesting the presence 
of interconversion between these two initially distinct 
populations. 
Amidated gastrin promotes cardia organoid 
growth through CCK2R
In order to confirm that gastrin can promote 
progression of Barrett’s-like esophagus in a direct manner 
by inducing proliferation in CCK2R+ cells, we studied 
cardia organoids from L2-IL-1β and WT mice. Organoids 
grown from the L2-IL-1β mouse cardia increased in 
number in response to gastrin in a dose-dependent manner 
(Figure 4A–4B). There was no increase in organoid size 
Figure 1: Hypergastrinemia accelerates Barrett’s-like esophagus in L2-IL-1β mice. (A) Schematic for omeprazole (OMP) 
treatment in wild type and L2-IL-1β mice. Mice were started on deoxycholic acid (0.2%) in their drinking water at 8 weeks of age, and 
then given omeprazole 200 mg/kg intraperitoneally 5 days a week, from 12 – 15 months of age. (B) Gastrin levels (pM) in L2-IL-1β mice 
(N = 5) and L2-IL-1β mice treated with omeprazole (N = 5) (p = 0.037).(C) Representative H&E stained sections from BE-like lesions at the 
SCJ of control and omeprazole-treated L2-IL-1β mice. (D) Dysplasia scores of BE-like lesions in control (N = 5) and OMP-treated (N = 5) 
L2-IL-1β mice (p < 0.05). (E) Goblet-like cell to columnar cell (GC) ratio from BE-like lesions in control (N = 5) and OMP-treated (N = 5) 
L2-IL-1β mice (p < 0.05). (F) Plasma gastrin levels (pM) in L2-IL-1β mice (N = 3) and L2-IL-1β/INS-GAS mice (N = 6) (p = 0.03). (G) H&E 
stained histological sections from the SCJ from wild type, INS-GAS, L2-IL-1β, L2-IL-1β/INS-GAS mice at 12 months of age. Outlined areas 
indicate BE mucinous metaplasia at the SCJ. Scale bars = 100 um. (H) CD44 immunostaining of cardia cells in WT, INS-GAS, L2-IL-1β, 
L2-IL-1β/INS-GAS mice. Scale bars = 100 um.
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Figure 2: Gastrin-dependent expansion of CCK2R+ cells in Barrett’s-like metaplasia. (A) Immunofluorescence for CCK2R 
(red) at the SJC in WT and L2-IL-1β mice treated with or without gastrin infusion, YF476 or both.  See Supplementary Methods for details 
of treatment. Sq indicates esophageal squamous mucosa at the SCJ. Arrows indicate CCK2R+ cells. (B) Quantification of CCK2R+ cells per 
cardia gland in WT and L2-IL-1β mice treated with or without gastrin infusion, YF476 or both.  (N = 5) (C) Representative sections showing 
Ki67 immunostaining from WT and L2-IL-1β mice treated with gastrin infusion with or without YF476. (D) Quantification of Ki67+ cells/
cardia gland in WT and L2-IL-1β mice treated with or without gastrin infusion, YF476 or both. (N = 3) (p = 0.01). (E) RT-PCR for Lgr5 
and CCK2R in the cardia of L2-IL-1β/INS-GAS mice (N = 6) compared to L2-IL-1β controls (N = 5) (p = 0.007 -CCK2R, p = 0.03 -Lgr5). 
(F) CCK2R immunostaining of normal human gastric cardia. (G) CCK2R immunostaining of human BE tissue with incomplete intestinal 
metaplasia (IM). (H) CCK2R immunostaining of human BE tissue with complete IM and adenocarcinoma.
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Figure 3: CCK2R marks long-lived progenitor cells in the cardia that give rise to Barrett’s-like metaplasia. (A) CCK2R-
CreERT/TdTom mice were tamoxifen-induced at 6 weeks of age, then sacrificed after 1, 7, 30, 90 and 360 days. Sq indicates squamous 
epithelium. Scale bars= 100 um. (B) CCK2R marks the cardia in CCK2R-Cre/tGFP mice. Green: recombined CCK2R+ cells; red: non-
recombined. Scale bars = 100 um. (C) Organoids grown for 24 h (left) and 7 days (right), isolated from the cardia of tamoxifen-treated 
CCK2R-CreERT/tGFP mice. Scale bars = 100 um. (D) L2-IL-1β/CCK2R-CreERT/R26r-TdTomato mice were tamoxifen-induced at 
6 weeks of age, then sacrificed after 1, 30, 90, and 360 days. Blue: DAPI. Red: CCK2R-CreERT recombined cells. Sq indicates squamous 
epithelium. Scale bars = 100 um. (E) Immunohistochemical staining for p63 (top) and CK20 (bottom) in 1-year old WT and L2-IL-1β 
mice.  Scale bars = 100 um. (F) Immunofluorescence for CCK2R in Lgr5-DTR-EGFP mouse cardia showing rare cells expressing both 
Lgr5 (green) and CCK2R (red). Red box is magnified on the right. Blue: DAPI. Sq indicates squamous epithelium.   Scale bars = 100 um. 
(G) Immunofluorescence images from CCK2R-CreERT/Lgr5-DTR-GFP/R26-TdTomato mice induced with tamoxifen and analyzed at 
2, 14 and 30 days. Arrows show double positive (Lgr5+ and CCK2R traced) cells. Scale bars = 100 um.
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with gastrin treatment (Figure 4C). The effect of gastrin 
on the number of L2-IL-1β cardia organoids was blocked 
by YF476, highlighting the specificity of gastrin/CCK2R 
signaling on organoid expansion. The expression of Cck2r 
and Lgr5 was significantly increased in gastrin-treated 
organoids in a dose-dependent manner compared to 
untreated organoids (Figure 4D), suggesting that amidated 
gastrin activates and expands the cardia progenitor 
compartment.
Blockade of CCK2R prevents the development 
of Barrett’s-like metaplasia in mice
To investigate whether gastrin blockade prevents the 
progression and proliferation of Barrett's-like esophagus 
cells, we treated L2-IL-1β mice with YF476 (Figure 5A) at 
6 months of age, when the first Barrett’s-like changes are 
observed at the SCJ. Mice were sacrificed at 15 months of 
age. CCK2R blockade increased systemic levels of gastrin in 
a compensatory manner (not shown). Nevertheless, YF476 
treatment led to a decrease in the dysplasia score, increased 
differentiated goblet-like cell to columnar cell (G/C) ratio, 
and decreased Ki67 index in cardia (Figure 5B–5E). 
L2-IL-1β mice treated with bile acids and MNU 
develop dysplastic lesions at an earlier age than mice 
treated with bile acids alone, and thus MNU/bile acid-
treated L2-IL-1β mice were also treated with YF476 or 
vehicle (Figure 5F). YF476 prevented the development 
of advanced dysplasia and markedly increased the mucus 
cell (G/C) ratio compared to controls (Figure 5G–5I). 
Furthermore, when L2-IL-1β/INS-GAS mice were treated 
with YF476, the dysplasia score in L2-IL-1β/INS-GAS 
mice was decreased and the mucus cell (G/C) ratio 
increased, indicating a strict dependence on CCK2R 
activation in these mouse phenotypes (Figure 5J, 5K). 
DISCUSSION
We demonstrate here that PPI-induced or genetic 
hypergastrinemia can increase the Barrett’s-like metaplasia 
phenotype in our L2-IL-1β mouse model, and that this can 
lead to accelerated progression to dysplasia. Blocking 
CCK2R with a small molecule inhibitor (YF476) in 
L2-IL-1β mice inhibited this effect. We have further 
shown that CCK2R, which is upregulated in human BE 
tissue, marks a long-lived gastric cardia progenitor cell 
that expands in the setting of chronic inflammation and 
hypergastrinemia and gives rise to Barrett’s-like esophagus 
in the L2-IL-1β mouse model. Hypergastrinemia could 
stimulate CCK2R+ cells in BE tissue to proliferate, 
and increased proliferation is correlated with less 
differentiation, less mucus (goblet-like) cell metaplasia in 
BE areas, and with accelerated malignant transformation. 
These findings suggest that elevated serum gastrin levels 
in BE patients warrants further study.
Importantly, hypergastrinemia enhanced the 
development of dysplasia within Barrett’s-like esophagus, 
particularly in MNU-treated animals. These findings are 
consistent with some human data, where BE patients 
with the highest gastrin levels were more likely to have a 
history of high-grade dysplasia or EAC [12]. It is possible 
that indirect effects of gastrin or PPIs could have had this 
effect. Hypergastrinemia is also known to induce acid 
secretion, which by itself could in theory have caused an 
accelerated phenotype in the INS-GAS mice. However, 
mice do not develop reflux esophagitis, and we have in 
the past excluded such a mechanism, since acidified water 
in the L2-IL-1β mouse model did not increase metaplasia 
and dysplasia [20]. Moreover, the fact that PPI treatment 
produced a similar phenotype to gastrin overexpression 
(in INS-GAS/L2-IL-1β mice) does point to the likelihood 
of direct effects of gastrin. Our data raises the possibility 
that hypergastrinemic states may worsen BE in patients 
with preexisting esophageal inflammation through 
providing a more carcinogenic niche that enables 
increased proliferation and less differentiation. 
Most epidemiologic studies suggest that PPIs reduce 
the risk of progression from BE to HGD or EAC, although 
there are no randomized placebo-controlled clinical trials 
demonstrating that PPIs have chemopreventive effects. The 
effect of PPIs on G/C ratio in BE patients has not been 
analyzed to our knowledge. A recent meta-analysis reported 
that PPI use in BE was associated with a significant 
reduction in the risk of progression to HGD or EAC 
(OR 0.29) [24]. However, 95–98% of all identified BE 
patients are treated with PPIs, and as such prior studies 
have lacked well-matched control groups. [24–26] 
Additionally, there has been some inconsistency with 
regard to the effects of PPI use on progression. In a nested 
case-control study using a Veterans’ Affairs database, PPI 
use was not associated with a reduced risk of EAC after 
adjusting for NSAID and statin use and other potential 
confounders [26]. Case-control studies from the UK and 
from Denmark have reported an increased risk of EAC in 
BE patients on PPIs [27, 28]. Importantly, few of the studies 
to date have accounted for gastrin levels in assessing the 
effects of PPIs on the risk of progression in BE. In a cross-
sectional study of BE patients on PPIs by Wang et al, 
those with the highest gastrin levels were significantly 
more likely to have a history of HGD or EAC [12]. If 
hypergastrinemia can contribute to carcinogenesis in BE, 
this has implications for continuing PPIs in patients who 
develop high gastrin levels on treatment.
However, PPIs have significant benefits in 
human BE, and omeprazole might worsen Barrett’s-
like esophagus in mice more so than in humans. Unlike 
humans, mice do not have acid reflux, which may promote 
proliferation and dysplasia [29], and which is reduced 
by PPIs [30, 31]. In humans, omeprazole decreases 
acid secretion and reduces duodenogastric reflux [32]. 
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In L2-IL-1β mice, however, the inflammatory esophagitis 
is genetically induced and maintained not by GERD but 
by the constitutive expression of IL-1β in the esophagus, 
rendering the esophagitis refractory to PPI treatment. 
Though this is a limitation of our model, L2-IL-1β mice 
were treated with bile acid in the drinking water to 
promote esophagitis, mimicking a mechanism by which 
BE can be accelerated by PPIs, as hypergastrinemia 
induces reduced gastric motility and therefore potentially 
more bile acid reflux. 
Hypergastrinemia in L2-IL-1β/INS-GAS mice led 
to increased stem cell markers in the cardia. We [20] 
and others [33] have previously demonstrated that Lgr5 
marks a long-lived stem cell in the cardia that can become 
activated in response to chronic inflammation. We show 
here that CCK2R also marks a long-lived progenitor cell 
in the cardia, similar to our earlier finding that CCK2R 
marks progenitors in the gastric antrum [18]. Cardia 
organoids from L2-IL-1β mice proliferate in response to 
gastrin stimulation, suggesting a model in which CCK2R+ 
Figure 4: Gastrin promotes cardia organoid growth through CCK2R. (A) Organoids grown from the gastric cardia of L2-IL-1β 
mice in 0 nM, 1 nM, 10 nM gastrin for 14 days. Scale bars =100 um. (B) Quantification of organoid number after 14 days of growth in 0 nM, 
1 nM, or 10 nM gastrin (*p = 0.01 0 nM vs 10 nM gastrin) from the gastric cardia L2-IL-1β mice. Treatment with YF476 (12 mg/mL) blocked 
the effect of gastrin on organoid number (p < 0.05 for all three gastrin doses). (C) Quantification of organoid diameter at day 1 and day 14 of 
growth in 0 nM, 1 nM, or 10 nM gastrin, in L2-IL-1β mice, with or without YF476 (12 mg/mL). YF476 had no effect on organoid diameter. 
(D) RT-PCR for CCK2R or Lgr5 from organoids of WT or L2-IL-1β cardia grown for 14 days in 0 nM, 1 nM or 10 nM gastrin. (***p < 0.001 
for all 4 dataset points: 1 nM gastrin WT and L2-IL-1β when compared to 0 nM gastrin WT and L2-IL-1β for CCK2R and Lgr5, respectively; 
and for 10 nM gastrin WT and L2-IL-1β when compared to 0 nM gastrin WT and L2-IL-1β for CCK2R and Lgr5, respectively).
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Figure 5: CCK2R blockade prevents the development of Barrett’s-like esophagus in L2-IL-1β mice. (A) Treatment 
schematic for L2-IL-1β mice with bile acid and YF476. Mice were started on deoxycholic acid (0.2%) in drinking water starting at 8 
weeks of age, and then given YF476 (30 mg/kg) intraperitoneally twice a week starting at 6 months of age. (B) Representative H&E 
stained histopathology sections showing extent of BE involvement in YF476-treated and untreated L2-IL-1β mice. Scale bars = 100 um. 
(C) Dysplasia scores in YF476-treated (N = 7) and untreated (N = 7) L2-IL-1β mice (p = 0.03). (D) Goblet cell (GC) ratio in YF476-treated (N = 7) 
and untreated (N = 7) L2-IL-1β mice (p = 0.03). (E) Ki-67 index in the cardia of YF476-treated (N = 7) and untreated (N = 7) L2-IL-1β mice 
(p = 0.01). (F) Treatment schematic for L2-IL-1β mice with bile acid, MNU, and YF476. Mice were started on deoxycholic acid (0.2%) in 
drinking water starting at 8 weeks of age, and then given MNU (240 ppm) in the drinking water starting at 4 months of age with one week on 
and one week off for 4 cycles. Thereafter, mice were treated with YF476 (30 mg/kg) by IP twice a week. (G) Representative H&E stained 
histopathologic sections showing extent of BE involvement in MNU-treated L2-IL-1β mice with (top) or without (bottom) YF476. Boxed 
area on left is magnified on right. Scale bars = 100 um. (H) Dysplasia scores in MNU-treated L2-IL-1β mice with (N = 7) or without (N = 8) 
YF476. (p = 0.03). (I) G/C ratio in MNU-treated L2-IL-1β mice with (N = 7) or without (N = 8) YF476 (p = 0.03). (J) Dysplasia scores in 
L2-IL-1β (N = 8), L2-IL-1β with YF476 (N = 7), L2-IL-1β/INS-GAS (N = 7), L2-IL-1β/INS-GAS with YF476 (N = 7) (*p < 0.05). (K) G/C 
ratios in L2-IL-1β (N = 8), L2-IL-1β with YF476 (N = 7), L2-IL-1β/INS-GAS (N = 7), L2-IL-1β/INS-GAS with YF476 (N = 7) (*p < 0.05).
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cells are “primed” by adjacent inflammation to proliferate 
in response to gastrin. In addition to marking cardia 
progenitor cells, CCK2R+ cells also gave rise to Barrett’s-
like metaplasia and dysplasia in L2-IL-1β mice. Thus, 
CCK2R represents a second marker linking Barrett’s-like 
metaplasia to its origin in the gastric cardia. CCK2R is not 
expressed at appreciable levels in the small intestine, yet 
numerous studies have now documented high levels of 
expression in human BE [19, 34]. similar to the increased 
cardia expression in our L2-IL-1β mice. Indeed, the finding 
that CCK2R+ cells can give rise to Barrett’s-like esophagus 
in mice is consistent with recent reports that human 
Barrett’s glands have an organizational structure similar 
to gastric glands, and probably start out within gastric 
metaplasia prior to acquiring intestinal features [35].
The transition from a normal CCK2R+ progenitor to 
a Barrett’s-like progenitor appeared to be largely driven by 
chronic inflammation. In our model, expression of IL-1β 
provided the necessary stimulus for SCJ inflammation that 
led to upregulation of CCK2R. While we could not verify 
whether IL-1β directly or indirectly induced CCK2R 
expression in cardia cells, our data strongly suggest that 
inflammation in the cardia due to the presence of IL-1β 
increased the number of gastrin-responsive progenitor 
cells. L2-IL-1β mice had a greater number of organoid-
forming progenitors in the gastric cardia compared to WT 
mice, consistent with an expansion of potential progenitors 
that could give rise to metaplasia and dysplasia. 
The expression of the CCK2R in the cardia appears 
to have functional significance. CCK2R expression is 
increased in the gastric mucosa in response to cryoinjury 
and other forms of gastric ulceration, where it contributes 
to the regenerative response to injury [16]. Epithelial cell 
proliferation during ulcer healing is inhibited by CCK2R 
blockade and stimulated by omeprazole and exogenous 
gastrin; however, CCK2R expression in this setting 
is typically transient and quickly downregulated [17]. 
Gastrin stimulation appears to have the same proliferative 
effect on Barrett’s epithelium, but in our model system this 
phenomenon was more long lasting.
In conclusion, our data suggest that hypergastrinemia 
promotes of progression and dysplasia in Barrett’s-like 
esophagus in our mouse model. The limitations of this 
mouse model warrants caution in extrapolating these 
data to human BE. However these findings suggest that 
in patients with BE, high gastrin levels warrant further 
longitudinal study and consideration of either trials of 
CCK2R inhibitors or more selective use of PPIs.
MATERIALS AND METHODS
Mice
L2-IL-1β mice were generated as described 
previously in a C57BL/6 background [20]. Eight-week 
old mice were given drinking water containing bile acids 
(0.2% deoxycholic acid, pH 7.0, Sigma, St. Louis, MO) 
for the duration of the study. Omeprazole (Sigma, St. 
Louis, MO) 200mg/kg/day was given intraperitoneally 
5 times weekly in a 1:1 mixture of dimethyl sulfoxide 
(DMSO) and PEG 300 at a concentration of 40mg/mL. 
INS-GAS, CCK2R-CreERT, CCK2R-Cre, Lgr5-DTR-
eGFP, Rosa26rLacZ, Rosa26rTdTom, and Rosa26rmTmG 
mice have been previously described [23]. Tissues from 
cardia were isolated as described in Figure S1. All murine 
experiments were performed in compliance with federal 
laws and institutional guidelines and approved by the 
IACUC of the Columbia University Animal Care Facility 
(protocol AAAF-2657). 
In lineage tracing studies, tamoxifen 5 mg was given 
by oral gavage. The gastrin receptor blocker, YF476 (kindly 
provided by Dr. Keiji Miyata and Dr. Hidenobu Yuki, 
Yamanouchi Pharmaceutical Co. Ltd., Tsukuba, Japan) was 
dissolved in PEG-300 (Sigma, St. Louis, MO) at 12 mg/mL 
(30 mg/kg) were given intraperitoneally twice weekly.
N-methyl-nitrosourea (MNU, Sigma, St. Louis, MO) 
was administered at 240 ppm in the drinking water for 
one week, followed by non-medicated water for one week, 
repeated 5 times over a total of 10 weeks.  After 10 weeks, 
drinking water with bile acids was resumed. 
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